P523
Poster Presentations: P2 patients who were performed with biomarker PET PiB and cognitive, neurological and psychiatric assessment. Patients with absence of beta-amyloid deposition -PiB negative status- (n ¼ 64) was separated, and the presumptive diagnoses reevaluated, according to DSM IV diagnostic criteria, presenting symptoms, neurocognitive assessment, and correlations with functional neuroimaging PET with FDG. Results: Of the 64 patients who had PiB negative status with cognitive or behavioral nonspecific presenting symptoms 40 patients (62.5%) continued with amnestic MCI diagnoses (23%), non-amnestic MCI (17%), and normal cognition (23%) without dementia or other diagnoses. Four patients (6.25%) were diagnosed as DTA, 3 patients (4.68%) were diagnosed as FTD, and 4 (6.25%) were APP. Five patients (8%) had a final diagnosis of depression, and 1 in bipolar disorder. Conclusions: Beyond AD, the PiB biomarker may be useful in the diagnostic workup of patients with cognitive / behavioral symptoms. The absence of amyloid can add a new element for guiding the clinician in the diagnostic context of each case. P2-141
BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) POLYMORPHISMS ARE ASSOCIATED WITH DIFFERENTIAL RATES OF AMYLOID ACCUMULATION AND COGNITIVE DECLINE IN COGNITIVELY NORMAL OLDER ADULTS
Jazmin Acosta1, Yonas E. Geda1, Gorazd B. Stokin2, Adam S. Fleisher3, Cole Reschke3, Robert J. Bauer, III,3, Pradeep Thiyyagura3, Bai Lu4, Richard J. Caselli1, Michael Weiner5, Eric M. Reiman3, Kewei Chen3, 1 Mayo Clinic, Scottsdale, Arizona, United States; 2St. Anne’s University Hospital Brno, Brno, Czech Republic; 3Banner Alzheimer’s Institute, Phoenix, Arizona, United States; 4Tsinghua University, Beijing, China; 5 University of California San Francisco, San Francisco, California, United States. Contact e-mail:
[email protected] Background: Among cognitively unimpaired persons with florbetapir positron emission tomography (PET) evidence of significant fibrillar amyloid-b (Ab) burden from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study, carriers of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism were distinguished from non-carriers by greater 36-month rates of memory, language, executive function, and hippocampal volume declines. Here, Alzheimer’s Disease Neuroimaging Initiative (ADNI) data were used to investigate whether baseline measurements and 24-month changes in fibrillar Ab deposition and neuropsychologist test scores were differentially affected by BDNF-Met carrier status in cognitively unimpaired individuals. Methods: 14 cognitively unimpaired BDNF-Met carriers, aged 76-94 years, and 20 non-carriers, aged 70-89 years, had baseline and 24-month follow-up clinical ratings, neuropsychological tests, florbetapir PET, and magnetic resonance imaging (MRI) scans. Standard uptake value ratios (SUVRs) with cerebellum reference region were used to quantify PET fibrillar Ab burden. T-tests were used to compare baseline measurements and 24-month changes in mean cortical florbetapir SUVRs, hippocampal volumes, and performance on 10 neuropsychological tests. Results: Except for age (carriers¼82.5265.78, non-carrie r s¼ 78.6364.49, p¼0.03), at baseline, BDNF-Met carriers and non-carriers did not differ in their gender ratios, years of education, proportions of apolipoprotein (APOE) ε4 carriers, Mini-Mental State Examination scores, florbetapir SUVRs, or hippocampal volumes. Interestingly, for baseline Auditory Verbal Learning Test (AVLT) scores, BDNF-Met carriers exhibited greater memory retention relative to non-carriers with (p¼0.05) or without (p¼0.03) accounting for age. BDNF-Met carriers were, however, distinguished from non-carriers by greater 24-month mean cortical florbetapir SUVR increases with ages accounted for (p¼0.003) or not (p¼0.02). Similarly, the BDNF-Met carriers had greater 24-month decline on AVLT long-term recall scores again with (p¼0.009) or without (p¼0.003) co-varying out age (but uncorrected for multiple neuropsychological tests). The groups, however, did not differ significantly in their 24-month changes of hippocampal volume or other neuropsychological test performance scores (p>0.05). Conclusions: This study raises the possibility that BDNF Val66Met allele is associated with accelerated rates of memory decline and greater amyloid deposition in cognitively normal adults. Additional studies are needed to confirm these preliminary findings and clarify the manner in which BDNF influences pathogenesis of Alzheimer’s disease.
P2-142
BRAINS FOR DEMENTIA RESEARCH: ASSESSMENT OF DEPRESSION IN THE COHORT
Gillian Hayes, Paul Francis, King’s College London, London, England, United Kingdom. Contact e-mail:
[email protected] Background: Brains for Dementia Research (BDR) www.brainsforde mentiaresearch.org.uk is a project involving planned brain donation following regular and standardised assessments of cognition, mood, behaviour and activities of daily living during life. Understanding the neuropathological and biochemical basis of mood and behavioural changes in people with dementia is becoming a relevant research area due to the paucity of effective medications. Here we review the available information on mood in the BDR cohort including those who have died. Methods: People with and without dementia in the BDR cohort had mood assessed either by the Geriatric Depression Scale (GDS) for controls or the Cornell Scale for Depression in Dementia (CSDD) dementia. Controls were assessed every 2-5 years and those with dementia every year. In many cases were dementia was present scores for the depression item of the Neuropsychiatric Inventory (NPI) were also available. Diagnosis of dementia: Normal MMSE 24-30, CDR¼0; MCI MMSE 24-30, CDR ¼0.5; dementia MMSE0.5 with supporting evidence of dementia. Some cases did not fall neatly into one of the categories and therefore were classed as uncertain. Results: A total of 366 individuals have had single assessments of mood to date while 375 participants have had 2 or more (a total of 900 assessments of mood were available, representing 41% 1st visit, 39% 2nd visits, 20% 3+ visits). The mean CSDD score for 112 assessments of participants with dementia was 5.86 (range 0-26) with 16% with scores above 9. The mean GDS for 704 assessments of control was 2.75 (range 0-29). 5% of assessments had scores above 9. The GDS score for MCI assessments was 6.10 and significantly higher than for assessment of controls (Mann-Whitney U, p
